semaglutide compound dosing Compounded Dosage Chart: Titration Guide Servings:150 Srvs Diet Stage_Weight Loss GLP1 receptor agonists are

semaglutide compound dosing Compounded Dosage Chart: Titration Guide Servings:150 Srvs Diet Stage_Weight Loss GLP1 receptor agonists are

GLP1 receptor agonists are supported by preclinical and observational evidence for reducing addictive behaviors, particularly alcohol and nicotine use. Initial randomized clinical trials indicate possible reductions in craving and substance intake, though

RCT STEP 9 - Semaglutide vs Placebo for Knee Osteoarthritis in Patients with Obesity, NEJM (2024) [PubMed abstract] The STEP 9 study enrolled 407 patients with BMI ≥ 30 and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain Main inclusion criteria Age 18 years or older BMI ≥ 30 ACR diagnostic criteria for knee OA Moderate X-ray changes (Kellgren-Lawrence grade 2 or 3) in target knee Knee OA WOMAC pain score of ≥ 40 Main exclusion criteria Use of opioid medications Use of obesity medication within 90 days Knee injection within 90 days Baseline characteristics Average age - 56 years Average weight - 239 lbs (108.6 kg) Average BMI - 40.3 Female sex - 82% Average WOMAC pain score - 70.9 Randomized treatment groups Group 1 (271 patients): Semaglutide 2.4 mg once weekly Group 2 (136 patients): Placebo Semaglutide was started at 0.24 mg once weekly and titrated over 16 weeks to 2.4 mg The percentage change in body weight and the change in the WOMAC pain score (scale 0 - 100, with higher scores meaning worse outcomes) from baseline to week 68 Primary outcome: Results Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo

Diet Stage_Weight Loss

Servings:150 Srvs

Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice